<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5F44D980-91F5-4741-B8D1-6E7FB9183303"><gtr:id>5F44D980-91F5-4741-B8D1-6E7FB9183303</gtr:id><gtr:name>Fudan University</gtr:name><gtr:address><gtr:line1>670 Guoshun Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/47977EA7-B9F8-4D02-9BD2-FD4D34F2644D"><gtr:id>47977EA7-B9F8-4D02-9BD2-FD4D34F2644D</gtr:id><gtr:name>Genomics England</gtr:name><gtr:address><gtr:line1>Queen Mary University of London</gtr:line1><gtr:line2>Dawson Hall</gtr:line2><gtr:line3>Charterhouse Square</gtr:line3><gtr:postCode>EC1M 6BQ</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7F72449F-A5FF-43A2-BCC0-0D544896C6C4"><gtr:id>7F72449F-A5FF-43A2-BCC0-0D544896C6C4</gtr:id><gtr:name>Nicosia State Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AB871950-0395-4429-A864-DBE2C1F8A574"><gtr:id>AB871950-0395-4429-A864-DBE2C1F8A574</gtr:id><gtr:name>University of Cyprus</gtr:name><gtr:address><gtr:line1>75 Kallipoleos Street</gtr:line1><gtr:line2>PO BOX 20537</gtr:line2><gtr:line3>1678, Nicosia</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5F44D980-91F5-4741-B8D1-6E7FB9183303"><gtr:id>5F44D980-91F5-4741-B8D1-6E7FB9183303</gtr:id><gtr:name>Fudan University</gtr:name><gtr:address><gtr:line1>670 Guoshun Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/47977EA7-B9F8-4D02-9BD2-FD4D34F2644D"><gtr:id>47977EA7-B9F8-4D02-9BD2-FD4D34F2644D</gtr:id><gtr:name>Genomics England</gtr:name><gtr:address><gtr:line1>Queen Mary University of London</gtr:line1><gtr:line2>Dawson Hall</gtr:line2><gtr:line3>Charterhouse Square</gtr:line3><gtr:postCode>EC1M 6BQ</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7F72449F-A5FF-43A2-BCC0-0D544896C6C4"><gtr:id>7F72449F-A5FF-43A2-BCC0-0D544896C6C4</gtr:id><gtr:name>Nicosia State Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB871950-0395-4429-A864-DBE2C1F8A574"><gtr:id>AB871950-0395-4429-A864-DBE2C1F8A574</gtr:id><gtr:name>University of Cyprus</gtr:name><gtr:address><gtr:line1>75 Kallipoleos Street</gtr:line1><gtr:line2>PO BOX 20537</gtr:line2><gtr:line3>1678, Nicosia</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/40F92293-6DA4-49EA-80F7-7A7B11EF92F7"><gtr:id>40F92293-6DA4-49EA-80F7-7A7B11EF92F7</gtr:id><gtr:firstName>Daniel</gtr:firstName><gtr:surname>Gale</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002528"><gtr:id>02AF8846-7916-4449-BAAC-867E65A4462F</gtr:id><gtr:title>Unravelling clinical and biochemical aspects of CFHR5</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1002528</gtr:grantReference><gtr:abstractText>I have recently discovered an inherited kidney disease called ?CFHR5 nephropathy? among people with Cypriot ancestry living in London, and found that the disease is a common cause of kidney failure in Cyprus. The disease is caused by a change in the gene ?CFHR5? which is thought to play a role in controlling a part of the immune system (the body?s defences against infection) called complement. The aims of this project are to understand firstly the function of the CFHR5 gene in healthy people, secondly how this function is altered in people with CFHR5 nephropathy, and thirdly how the disease can best be treated. In addition, the project aims to find out what role CFHR5 plays in other common kidney diseases as it may be that CFHR5 offers a completely new type of treatment for them.
I will do this by studying the function of the gene in the laboratory and looking for other abnormalities in CFHR5 in people with unexplained kidney disease. I will also give the drug called eculizumab (currently in routine use for a different disease) to people with CFHR5 nephropathy to test whether it protects them from kidney failure.</gtr:abstractText><gtr:technicalSummary>Disordered regulation of complement contributes to a range of diseases including cardiovascular disease, age related macular degeneration and glomerulonephritis. During my MRC Clinical Research Training Fellowship I identified a novel monogenic disease, Complement Factor H-Related 5 (CFHR5) nephropathy, which causes complement dysregulation in the kidney. The disease is associated with a mutation in the CFHR5 gene (a homologue of CFH) and is a common cause of renal failure among Cypriots. As well as defining a clinical cohort with a unified disease pathophysiology, these findings implicate CFHR5 as an important regulator of complement. The mechanism by which the mutation causes disease is not understood.
CFHR5: structure and functional relationships 
I will measure the affinity of CFHR5 proteins for other components of the complement system (including Factor I, C5 and C3) and initiate crystal structure determinations of the mutant and wild-type CFHR5 proteins. This will establish the major biochemical properties of CFHR5, using the mutant protein to highlight those properties with significance in CFHR5 nephropathy.
Frequency of CFHR5 nephropathy
I have identified over 100 patients with CFHR5 nephropathy in London and Cyprus, and will establish a registry of patients with this and other CFHR5 abnormalities to identify prognostic markers which correlate with outcomes. The high prevalence of CFHR5 nephropathy in Cypriots is unexplained. While this could result from genetic drift, enhanced complement activation may protect against an infectious organism present in Cyprus, selecting for the mutation. I will measure the ability of patient and control serum to opsonise microorganisms, using recombinant proteins to determine if any differences result from the CFHR5 mutation.
CFHR5 in other diseases
Complement deposition is common in glomerulonephritides, including mesangiocapillary glomerulonephritis, IgA nephropathy and lupus nephritis. I will develop an assay for circulating CFHR5 to determine its utility as a biomarker for glomerular inflammation in these diseases. In addition, I will administer the CFHR5 proteins to mice with experimentally induced glomerulonephritis to determine whether human CFHR5 can ameliorate renal injury.
Other CFHR5 mutations
I have collected DNA samples from patients and families with unexplained hereditary glomerulonephritis. I will use linkage exclusion mapping and molecular genetic techniques to determine whether other mutations in CFHR5 cause kidney disease among this population.
Treatment of CFHR5 nephropathy 
I will set up an experimental study to test whether eculizumab (a clinically licensed monoclonal antibody against C5) influences the disease.</gtr:technicalSummary><gtr:fund><gtr:end>2015-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1022548</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cyprus</gtr:collaboratingOrganisation><gtr:country>Cyprus, Republic of</gtr:country><gtr:department>Molecular Medicine Research Center</gtr:department><gtr:description>Investigation of CFHR5</gtr:description><gtr:id>678959C2-4CDE-4C0E-851A-513C42D4C08A</gtr:id><gtr:impact>Helped secure further funding for the project.</gtr:impact><gtr:outcomeId>sLK3LzdB2Rm-1</gtr:outcomeId><gtr:partnerContribution>Has allowed access to clinicians, patients and expertise from Cyprus for the study of CFHR5 nephropathy</gtr:partnerContribution><gtr:piContribution>Identification of a newly recognised genetic cause of renal failure which is endemic in Cyprus.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Biosciences</gtr:department><gtr:description>Unravelling the molecular roles of the CFHRs</gtr:description><gtr:id>BD125C5F-9AF5-44D7-9EBB-BCA8171A6D64</gtr:id><gtr:impact>Funding for PhD student obtained</gtr:impact><gtr:outcomeId>ZfMGLybdYud-1</gtr:outcomeId><gtr:partnerContribution>Biophysics expertise and infrastructure to study molecular interactions and structure.</gtr:partnerContribution><gtr:piContribution>Identification and recruitment of patients with mutations in the proteins. Recombinant production of protein.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fudan University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Nephrology</gtr:department><gtr:description>Genetics of IgA nephropathy</gtr:description><gtr:id>9986E099-BCAB-4501-91B9-F4F2794C033F</gtr:id><gtr:impact>Publication in seciton 1: PMID 20031928</gtr:impact><gtr:outcomeId>ha2d2qssKsf-1</gtr:outcomeId><gtr:partnerContribution>Assembly of DNA databank.</gtr:partnerContribution><gtr:piContribution>SNP genotyping and statistical analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Genomics England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Genomics England Clinical Interpretation Partnership</gtr:description><gtr:id>900F0548-937F-4B50-B9A2-BC5235D590EC</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56d48b6e87e347.39676128-1</gtr:outcomeId><gtr:partnerContribution>Perform whole genome sequencing of UK patients with kidney disease.</gtr:partnerContribution><gtr:piContribution>Developed eligibility statements and data models for enrollment of patients with kidney disease in 100,000 genomes project. Communicated with UK experts in renal disease to facilitate analysis of genome data.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nicosia State Hospital</gtr:collaboratingOrganisation><gtr:country>Cyprus, Republic of</gtr:country><gtr:description>Kidney Disease in Northern Cyprus</gtr:description><gtr:id>78CD4A03-5397-46C4-9CF5-A1895041D5C7</gtr:id><gtr:impact>PMID: 23349874</gtr:impact><gtr:outcomeId>qtERHnKSeWU-1</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients with kidney disease from Northern Cyprus</gtr:partnerContribution><gtr:piContribution>Population and genetic analysis of kidney disease in Northern Cyprus</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Organised and chaired national patient education day for polycystic kidney disease</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9B3FCDAA-7E1E-4D9A-85AD-82C594B41068</gtr:id><gtr:impact>The patient education day provided patients and carers with information about clinical issue and research in polycystic kidney disease. It was very well-attended and the speakers received extremely positive feedback</gtr:impact><gtr:outcomeId>56d48412101203.87394827</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Speaker at national patient day for membranoproliferative glomerulonephritis</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>065681C5-3380-4ED7-8DA6-98A954823C8D</gtr:id><gtr:impact>Spoke to an audience consisting of patients and families wiht the rare kidney disease membranoproliferative glomerulonephritis

The patient day was very well attended and feedback from attendees was universally good. The talk was filmed and uploaded onto YouTube and has had in excess of 50 views.</gtr:impact><gtr:outcomeId>Ac74JND8dpo</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.mpgn.org.uk/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient education day - Alport Syndrome</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>110E4EEC-568A-4502-94FC-2C73419383BC</gtr:id><gtr:impact>Spoke to a rare diseases patient group about participation in clinical trials, including answering specific questions regarding the trials in their disease. This stimulated interest in trial participation.</gtr:impact><gtr:outcomeId>58add27d0207b6.39611397</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.alportuk.org/news/alport-uk-information-day-7th-january-2017</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>55000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Kidney Cancer Grant</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>St Peter's Trust for Kidney, Bladder and Prostate Research</gtr:fundingOrg><gtr:id>7E81F04A-8FB8-4D1E-8B6F-58B9DB198B8B</gtr:id><gtr:outcomeId>56d48015923241.10004074</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>33000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Impact PhD studentship</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Rosetrees Trust</gtr:fundingOrg><gtr:fundingRef>M187</gtr:fundingRef><gtr:id>278A7CB0-54D9-4407-98EB-9BCA8274B072</gtr:id><gtr:outcomeId>56d48107d473a7.97260677</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1022548</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinician Scientist Award</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1002528</gtr:fundingRef><gtr:id>496F415F-545C-4CD4-88F0-507496B5CFB7</gtr:id><gtr:outcomeId>FeNRZLkwHNH0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>149000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>John Feehally-Stoneygate Award</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:fundingRef>JF-S_RP_2015_1</gtr:fundingRef><gtr:id>A163D390-1D96-4AC5-829E-0CBE49C91A3C</gtr:id><gtr:outcomeId>56d47d5545b529.46113351</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>125000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GIKD Research Grant</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Rosetrees Trust</gtr:fundingOrg><gtr:fundingRef>M260-CD1</gtr:fundingRef><gtr:id>87B4776A-6DFB-4C90-938F-644292EA8721</gtr:id><gtr:outcomeId>fprZvHw19bd</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>WGIKD Impulsion Grant</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)</gtr:fundingOrg><gtr:id>59D732FB-4485-407E-B8DB-68D62F623D82</gtr:id><gtr:outcomeId>TM2svSFtDWR</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>54000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Translational Research Collaboration</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>495F40F6-BDE8-47D4-AE02-C4A5EA1A0E8E</gtr:id><gtr:outcomeId>56d47c7b73d416.81482711</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of international working group on C3 glomerulopathy</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>286610B8-A66E-4DF7-AB3B-0D83414E6E39</gtr:id><gtr:outcomeId>gTBUBDza3Jf</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Introduction of new clinical genetic test for kidney disease</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>D15FF88A-10F5-4345-B8F0-29E7FAA36F32</gtr:id><gtr:outcomeId>CxombUsLk95</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>The clinical genetic test for CFHR5 nephropathy is now in use in clinical genetic laboratories in the UK and Cyprus. Its invention and development was funded by and MRC research grant.</gtr:description><gtr:id>8679AD9B-A01F-48E2-B6AC-121E2079F60A</gtr:id><gtr:impact>This test has provided a firm diagnosis for over 100 patients with otherwise unexplained kidney disease worldwide, obviating the need for kidney biopsy in some of these people.</gtr:impact><gtr:outcomeId>sRXStixu6UK</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Genetic test for CFHR5 nephropathy</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>Genetic analysis tool that enables identification of shared genomic regions in sets or subsets of related or unrelated individuals using dense bi-allelic marker or massively parallel sequencing data.</gtr:description><gtr:id>E662F32C-4B7B-4220-940D-C80F88559E19</gtr:id><gtr:impact>This tool allowed identification of locus harbouring pathogenic mutation responsible for disease in 2 families (Edwards et al Clin Kidney J 2015 and Levine et al BMC Genomics 2015.)</gtr:impact><gtr:outcomeId>55095ce3249c75.39415806</gtr:outcomeId><gtr:title>Combinatorial Conflicting Homozygosity (CCH) analysis tool</gtr:title><gtr:type>Software</gtr:type><gtr:url>http://sourceforge.net/projects/cchsnp/</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7C084144-2E5D-4B2C-B745-EEE909CC2EEB</gtr:id><gtr:title>Low a-defensin gene copy number increases the risk for IgA nephropathy and renal dysfunction.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe3fdbd0e5c1abdbe44c850155dc4ec8"><gtr:id>fe3fdbd0e5c1abdbe44c850155dc4ec8</gtr:id><gtr:otherNames>Ai Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>58adaab57f9a60.72337529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59EAAD71-2BED-497B-89A1-4BD9312264F1</gtr:id><gtr:title>Attitudes in Patients with Autosomal Dominant Polycystic Kidney Disease Toward Prenatal Diagnosis and Preimplantation Genetic Diagnosis.</gtr:title><gtr:parentPublicationTitle>Genetic testing and molecular biomarkers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ea3bcb6715fcf36bcc04c13ce661c53"><gtr:id>8ea3bcb6715fcf36bcc04c13ce661c53</gtr:id><gtr:otherNames>Swift O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1945-0257</gtr:issn><gtr:outcomeId>58adaab4615ad8.45436549</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D542938-1469-4177-9117-51A401D0F802</gtr:id><gtr:title>C3 glomerulonephritis/CFHR5 nephropathy is an endemic disease in Cyprus: clinical and molecular findings in 21 families.</gtr:title><gtr:parentPublicationTitle>Advances in experimental medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78fb63ab3a17c9066e5ccc2b8b481a2e"><gtr:id>78fb63ab3a17c9066e5ccc2b8b481a2e</gtr:id><gtr:otherNames>Deltas C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0065-2598</gtr:issn><gtr:outcomeId>pm_14077_27_23402027</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CF4B222-7A73-4CA5-88E4-386EF04A5DE4</gtr:id><gtr:title>Isolated microscopic haematuria of glomerular origin: clinical significance and diagnosis in the 21st century.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aef649d673776ea09dfa5d4849482262"><gtr:id>aef649d673776ea09dfa5d4849482262</gtr:id><gtr:otherNames>Chan MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>56d47af1d8a059.71666479</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21F14A15-49FE-4E46-8D0F-B59826441909</gtr:id><gtr:title>A novel COL4A1 frameshift mutation in familial kidney disease: the importance of the C-terminal NC1 domain of type IV collagen.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85c5abe4453271914e4bb8815c9c1c50"><gtr:id>85c5abe4453271914e4bb8815c9c1c50</gtr:id><gtr:otherNames>Gale DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>58adaab42880e6.45801057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C7F39F3-359A-4002-AC07-CAEDE1AADFF2</gtr:id><gtr:title>Mutations in mitochondrial DNA causing tubulointerstitial kidney disease.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9a445c00d4a496e57ee743091335841"><gtr:id>e9a445c00d4a496e57ee743091335841</gtr:id><gtr:otherNames>Connor TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>58c2da46b62845.40909835</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67D87D48-D062-467A-BB97-E52101D66606</gtr:id><gtr:title>Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f467930482c1fdb4e79d78b295a81332"><gtr:id>f467930482c1fdb4e79d78b295a81332</gtr:id><gtr:otherNames>Gross O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>58adaab4c8ec97.11675880</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A93744B2-55B4-4181-B6BF-1AF9B9429EE2</gtr:id><gtr:title>Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a28f2f545ecea8c08c615f27af64f94c"><gtr:id>a28f2f545ecea8c08c615f27af64f94c</gtr:id><gtr:otherNames>Kavanagh D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>58adaab49356b5.93633580</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C077B5AE-033E-4FC1-B00D-9EB43773BE7D</gtr:id><gtr:title>Genetic testing can resolve diagnostic confusion in Alport syndrome.</gtr:title><gtr:parentPublicationTitle>Clinical kidney journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d8eb0094a3f8d66dfc5cd90d4814fc2"><gtr:id>3d8eb0094a3f8d66dfc5cd90d4814fc2</gtr:id><gtr:otherNames>Adam J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2048-8505</gtr:issn><gtr:outcomeId>pm_14077_27_24944784</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5BA5F72-1423-4651-8F30-B2FC717DE29E</gtr:id><gtr:title>Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01fae2d0af62cee2357c2b0799e49047"><gtr:id>01fae2d0af62cee2357c2b0799e49047</gtr:id><gtr:otherNames>Scully M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>58adaab54c0503.45669000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59B02F63-B2DE-4987-8D0B-A0A16FF8C190</gtr:id><gtr:title>Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c334fa46bda1a6a08ffe8827a59a239b"><gtr:id>c334fa46bda1a6a08ffe8827a59a239b</gtr:id><gtr:otherNames>Kiryluk K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5460b9f1e32d28.24422668</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66B288D1-0ECD-4716-9E01-15F6D3AE5BBA</gtr:id><gtr:title>Galactosylation of IgA1 Is Associated with Common Variation in.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85c5abe4453271914e4bb8815c9c1c50"><gtr:id>85c5abe4453271914e4bb8815c9c1c50</gtr:id><gtr:otherNames>Gale DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>58adaab370cd76.14296368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0DA30AA-37DC-4610-AE66-7AFE45A8D331</gtr:id><gtr:title>A novel LMX1B mutation in a family with end-stage renal disease of 'unknown cause'.</gtr:title><gtr:parentPublicationTitle>Clinical kidney journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc8ed093e021d4019d1b7c657b040421"><gtr:id>dc8ed093e021d4019d1b7c657b040421</gtr:id><gtr:otherNames>Edwards N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2048-8505</gtr:issn><gtr:outcomeId>55095a83afae20.51720706</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF26A6BE-ACC3-40EB-848A-4BD0548B20FB</gtr:id><gtr:title>The solution structure of the human complement regulator CFHR5 reveals a compact dimeric structure by X-ray scattering and analytical ultracentrifugation</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b6d43f71173be0b2a29bc2ebce1c09a"><gtr:id>3b6d43f71173be0b2a29bc2ebce1c09a</gtr:id><gtr:otherNames>Kadkhodayi-Kholghi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn><gtr:outcomeId>58c2dbecefff78.25073307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61FA7DEB-4B3B-4023-8E35-0E749895C92F</gtr:id><gtr:title>Combinatorial Conflicting Homozygosity (CCH) analysis enables the rapid identification of shared genomic regions in the presence of multiple phenocopies.</gtr:title><gtr:parentPublicationTitle>BMC genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/883491ed856902c61f608691285072f4"><gtr:id>883491ed856902c61f608691285072f4</gtr:id><gtr:otherNames>Levine AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2164</gtr:issn><gtr:outcomeId>55095a83e9d971.34001244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2340B425-B37A-43BB-8C58-6CDAB05853DE</gtr:id><gtr:title>Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c01a15d3a976ca641e6ea237d4eb9c9c"><gtr:id>c01a15d3a976ca641e6ea237d4eb9c9c</gtr:id><gtr:otherNames>Osborne AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5a9d014617f9b2.76951595</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87F5DCA7-FE08-4C0E-A16E-F50337AF60DF</gtr:id><gtr:title>Regulating complement in the kidney: insights from CFHR5 nephropathy.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85c5abe4453271914e4bb8815c9c1c50"><gtr:id>85c5abe4453271914e4bb8815c9c1c50</gtr:id><gtr:otherNames>Gale DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn><gtr:outcomeId>pm_14077_27_22065842</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C798C4F-C8A2-4684-9D88-2E2A3B64E9C6</gtr:id><gtr:title>Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61711e17c223459294a27a3946aed64a"><gtr:id>61711e17c223459294a27a3946aed64a</gtr:id><gtr:otherNames>Carss KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>58adaab50bb538.64134060</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29848AD3-8534-40CA-8B7E-4DFED47F20BB</gtr:id><gtr:title>The 2014International Workshop on Alport Syndrome.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1fa56940e381fec523db0db04cf3f6a"><gtr:id>b1fa56940e381fec523db0db04cf3f6a</gtr:id><gtr:otherNames>Miner JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>5460b9f23de8e1.22790339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF93BF47-9072-4E41-9C33-023C4F520349</gtr:id><gtr:title>Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a &amp;quot;Kidney Disease: Improving Global Outcomes&amp;quot; (KDIGO) Controversies Conference.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b62de757d0b7667ae5eaf0be26b011d1"><gtr:id>b62de757d0b7667ae5eaf0be26b011d1</gtr:id><gtr:otherNames>Goodship TH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>58adaab3a00832.34161747</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58ED397E-359B-4322-BD0E-1D3E03226989</gtr:id><gtr:title>How benign is hematuria? Using genetics to predict prognosis.</gtr:title><gtr:parentPublicationTitle>Pediatric nephrology (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85c5abe4453271914e4bb8815c9c1c50"><gtr:id>85c5abe4453271914e4bb8815c9c1c50</gtr:id><gtr:otherNames>Gale DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0931-041X</gtr:issn><gtr:outcomeId>pm_14077_27_23325022</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7DBBA57-B934-4797-8BF7-F7F0D02148E4</gtr:id><gtr:title>Epistatic role of the MYH9/APOL1 region on familial hematuria genes.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a543f50a01b5e71d7dc808ea334ba9a"><gtr:id>9a543f50a01b5e71d7dc808ea334ba9a</gtr:id><gtr:otherNames>Voskarides K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14077_27_23516419</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1AA6AED-F3BF-4287-871F-FB12F1C769BE</gtr:id><gtr:title>Frequent COL4 mutations in familial microhematuria accompanied by later-onset Alport nephropathy due to focal segmental glomerulosclerosis.</gtr:title><gtr:parentPublicationTitle>Clinical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db1b9d213fd83695437192fc4c515580"><gtr:id>db1b9d213fd83695437192fc4c515580</gtr:id><gtr:otherNames>Papazachariou L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-9163</gtr:issn><gtr:outcomeId>5a8adb50d292a8.23012786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB729EFA-97BB-4FC9-9F42-4667205F52B1</gtr:id><gtr:title>Whole exome sequencing reveals novel COL4A3 and COL4A4 mutations and resolves diagnosis in Chinese families with kidney disease.</gtr:title><gtr:parentPublicationTitle>BMC nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f18ad6a1ed5da875b8a7e3c3966b8830"><gtr:id>f18ad6a1ed5da875b8a7e3c3966b8830</gtr:id><gtr:otherNames>Lin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2369</gtr:issn><gtr:outcomeId>5460b9f21865f5.35265849</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>119C6C5F-606D-49B5-A994-1ABC25B98F08</gtr:id><gtr:title>A functional variant in NEPH3 gene confers high risk of renal failure in primary hematuric glomerulopathies. Evidence for predisposition to microalbuminuria in the general population.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a543f50a01b5e71d7dc808ea334ba9a"><gtr:id>9a543f50a01b5e71d7dc808ea334ba9a</gtr:id><gtr:otherNames>Voskarides K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a8adb51262127.52190039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D071D49F-D0E6-4AA6-9B27-8CF2978565D2</gtr:id><gtr:title>HNF1B Genetic Testing In a Turkish Cypriot Population with a High Incidence of Familial Kidney Disease</gtr:title><gtr:parentPublicationTitle>Journal of Nephrology &amp; Therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a6947c25f64b92e7748c6662c774108"><gtr:id>7a6947c25f64b92e7748c6662c774108</gtr:id><gtr:otherNames>L Clissold R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>56daca756c6444.35975529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A35B35E4-6CA9-414F-BD18-0628A0D7045B</gtr:id><gtr:title>C3 glomerulonephritis and CFHR5 nephropathy.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85c5abe4453271914e4bb8815c9c1c50"><gtr:id>85c5abe4453271914e4bb8815c9c1c50</gtr:id><gtr:otherNames>Gale DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>pm_14077_27_23125424</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F748DE4D-CB80-4009-BB47-9A18FF31EBF2</gtr:id><gtr:title>The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cf190801a009a97de3a4018536a7f03"><gtr:id>6cf190801a009a97de3a4018536a7f03</gtr:id><gtr:otherNames>Phillips EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>56d47af18d8fc6.63558319</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF6755B5-248D-4D86-8D33-BA6C47F84681</gtr:id><gtr:title>Incidence of end-stage renal disease in the Turkish-Cypriot population of Northern Cyprus: a population based study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9a445c00d4a496e57ee743091335841"><gtr:id>e9a445c00d4a496e57ee743091335841</gtr:id><gtr:otherNames>Connor TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14077_27_23349874</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B9A1348-39A8-4BBB-9FED-E52F70096FB2</gtr:id><gtr:title>C3 glomerulopathy: consensus report.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c6895bcbeb40103b166b460184e6560"><gtr:id>7c6895bcbeb40103b166b460184e6560</gtr:id><gtr:otherNames>Pickering MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>pm_14077_27_24172683</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002528</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>